Opicapone as First-line Strategy for the Treatment of Wearing-off in Patients with Parkinson’s Disease (P7-5.026)
The Korean and European ADOPTION studies aimed to explore the efficacy of opicapone (OPC) 50 mg versus an additional 100 mg levodopa dose to treat early wearing-off in patients with Parkinson’s disease (PD).
Authors
- Joaquim José Ferreira (ORCID: https://orcid.org/0000-0003-3950-5113)
- Hyeo‐Il Ma (ORCID: https://orcid.org/0000-0001-6733-9779)
- Daniela Rodrigues (ORCID: https://orcid.org/0000-0002-4559-4303)
- Miguel M. Fonseca (ORCID: https://orcid.org/0000-0003-4598-670X)
- Fabrizio Stocchi (ORCID: https://orcid.org/0000-0002-5763-0033)
- Angelo Antonini (ORCID: https://orcid.org/0000-0003-1040-2807)
- Olivier Rascol (ORCID: https://orcid.org/0000-0002-1410-6397)
- Werner Poewe (ORCID: https://orcid.org/0000-0003-4367-0971)
- José‐Francisco Rocha (ORCID: https://orcid.org/0000-0003-2611-4850)
- Stanley Fisher
- Guillermo Castilla‐Fernández
- Jee‐Young Lee (ORCID: https://orcid.org/0000-0002-9120-2075)
- Joerg Holenz
- Beomseok Jeon
Institutions
- University of Lisbon (PT)
- Innsbruck Medical University (AT)
- Vita-Salute San Raffaele University (IT)
- Inserm (FR)
- Universität Innsbruck (AT)
- Seoul National University Hospital (KR)
- Amneal (India) (IN)
- SNUH SMG-SNU Boramae Medical Center (KR)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Hallym University Sacred Heart Hospital (KR)
- French Clinical Research Infrastructure Network (FR)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210479
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00